Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Immuron Limited is a biotechnology company focused on developing and commercializing novel therapeutic products based on its proprietary immunotherapy platform. The company is particularly active in the areas of gastrointestinal disorders and infectious diseases, with its lead product, Travelan, aimed at preventing travelers' diarrhea. Its unique competitive advantage lies in its patented technology that leverages polyclonal antibodies derived from hyperimmune bovine serum.
Immuron generates revenue primarily through the sale of its lead product, Travelan, which is marketed as a preventative treatment for travelers' diarrhea. The company has a strong pricing power due to the unique nature of its product and its limited competition in the market. Its competitive advantages include proprietary technology and a strong brand reputation in niche markets.
Regulatory approvals for new products or indications
Sales growth of Travelan in international markets
Partnerships or licensing agreements with larger pharmaceutical companies
Clinical trial results for pipeline products
Regulatory changes impacting drug approval processes
Technological disruption from new treatment modalities
Emergence of generic alternatives to Travelan
Increased competition from other biotech firms in gastrointestinal therapeutics
Liquidity risk due to negative cash flows
Dependence on external financing for R&D initiatives
moderate - The demand for healthcare products can be somewhat insulated from economic cycles, but overall consumer spending on healthcare can be affected by economic downturns.
Interest rates affect the company's cost of capital and financing for R&D projects. Higher rates could increase financing costs, impacting the company's ability to fund operations and growth initiatives.
minimal - The company has no debt, which reduces its exposure to credit market fluctuations.
growth - Investors interested in high-risk, high-reward opportunities in the biotech sector.
high - The stock has shown significant price volatility, reflecting the inherent risks in biotech investments.
